Podcasts about Eli Lilly

American pharmacist, Union Army officer, businessman, philanthropist

  • 1,258PODCASTS
  • 3,224EPISODES
  • 27mAVG DURATION
  • 2DAILY NEW EPISODES
  • Sep 10, 2025LATEST
Eli Lilly

POPULARITY

20172018201920202021202220232024

Categories



Best podcasts about Eli Lilly

Show all podcasts related to eli lilly

Latest podcast episodes about Eli Lilly

Capital
Consultorio de bolsa con Miguel Méndez: “Inditex sube en bolsa pero no deslumbra en sus cuentas"

Capital

Play Episode Listen Later Sep 10, 2025 26:46


Miguel Méndez, Analista independiente comenta la situación de los valores bursátiles. Inditex es protagonista en el día de hoy con su presentación de resultados, y aunque el título sube, “las cuentas no arrojan un crecimiento deslumbrante” asegura. Aún así, Méndez confía que los resultados actúen como catalizador para que el valor recupere niveles y se acerque a los 49 euros. El experto financiero también ha analizado el sector farmacéutico con Novo Nordisk y Eli Lilly, que no atraviesan un momento especialmente positivo. Es por ello que Méndez no ve motivos suficientes para tomar posiciones en estas compañías. Mientras tanto, Lululemon, atraviesa dificultades causadas por los aranceles, lo que prolonga el sufrimiento bursátil. No obstante, apunta que “a los precios actuales la compañía ofrece potencial” y, a medio plazo, se inclina por mantenerla en cartera. Por último, muestra su confianza en Lotus Bakeries, valor en el que mantiene expectativas de que alcance los 10.000 puntos, con un nivel clave en los 9.140. “Me sigue gustando, creo en la empresa”, afirma.

TODAY with Hoda & Jenna
September 9, Nikki Glaser: Catching up with Julianne Moore | Hoda and an Inspiring Principal | Discussing the Latest with Chrissy Teigen

TODAY with Hoda & Jenna

Play Episode Listen Later Sep 9, 2025 36:55


Nikki Glaser joins Jenna in Studio 1A as co-host for the day. She answers a rapid-fire round of questions on the latest in pop culture and reveals some hot takes. Also, Julianne Moore joins to discuss her continued love for acting, her latest Netflix show ‘Sirens,' and her partnership with Eli Lilly. Plus, Hoda is back to share the story of a remarkable New Orleans principal who is inspiring her students and many others. And, Chrissy Teigen stops by to raise awareness about an issue very personal to her.

Managed Care Cast
Navigating the Alzheimer Disease Blood Test Revolution

Managed Care Cast

Play Episode Listen Later Sep 9, 2025 32:34


We discuss the May 16 FDA approval of the first blood test to diagnose Alzheimer disease. This landmark approval marks a significant shift in how Alzheimer disease is identified, moving away from more traditional methods or invasive methods. Our guests, Howard Fillit, the Alzheimer's Drug Discovery Foundation, and Anthony “Nino” Sireci, MD, MSc, Eli Lilly and Company, help us understand this “huge accomplishment" and how it may be able to transform the diagnostic landscape from one of nihilism to one of hope and early intervention.

Medical Sales U with Dave Sterrett
E27 | From Pharmacist to Pharma Rep: Breaking Into Specialty Sales

Medical Sales U with Dave Sterrett

Play Episode Listen Later Sep 8, 2025 27:03


From pharmacist to Eli Lilly sales rep in just 5 weeks.In this episode, Francesco Russo shares how he went from burnout in retail pharmacy to landing a high-paying role in pharmaceutical sales thanks to strategy, networking, and a customized plan. His story proves that even highly educated professionals need more than degrees to stand out.Do you want to break into pharma or medical sales? Learn the strategies Francesco used inside this episode.

ASCO eLearning Weekly Podcasts
Emerging Treatment Paradigms in Genitourinary Cancers

ASCO eLearning Weekly Podcasts

Play Episode Listen Later Sep 8, 2025 24:10


Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

MedChat
Alzheimer's Disease Early Diagnosis and Management

MedChat

Play Episode Listen Later Sep 8, 2025 21:27


Alzheimer's Disease Early Diagnosis and Management Evaluation and Credit:  https://www.surveymonkey.com/r/medchat82   Target Audience             This activity is targeted toward primary care physicians and advanced providers. Statement of Need A special report of Alzheimer's Disease Facts and Figures published in 2017, indicated 4 out of 5 Americans would want to know if they had Alzheimer's disease before it impacted their life. With the aging population the incidence of Alzheimer's is growing, according to the Alzheimer's Association over 7 million Americans are living with AD. This program will focus on screening and dx of AD in the early stages especially in pc offices, where patients will first present with cognitive symptoms. Additionally, this podcast will highlight the new blood biomarker test recently approved and its indications. Objectives  Differentiate between normal cognitive aging, mild cognitive impairment and early-stage Alzheimer's disease. Identify appropriate cognitive screening tools for use in primary care and their role in the early identification of Alzheimer's disease. Explain the mechanism and clinical relevance of blood-based biomarkers in the diagnosis of Alzheimer's disease, including the current guidelines and emerging practices. ModeratorRachel Hart, D.O. Geriatric Medicine Physician Memory and Cognitive Disorders Specialist Norton Neuroscience Institute Memory Center SpeakerGreg E. Cooper, M.D., Ph.D. Chief, Adult Neurology Medical Director, Memory Center Norton Neuroscience Institute   Planner Disclosure  The planners of this activity do not have any relevant financial relationships with ineligible companies to disclose. Moderator and Speaker DisclosureThe moderator, Gregory Cooper, M.D., Ph.D., discloses relevant financial relationships with Eli Lilly and Eisai (research). The speaker, Rachel Hart, D.O., discloses a relevant financial relationship with Eli Lilly (faculty).  All relevant financial relationships have been successfully mitigated. Commercial Support  There was no commercial support for this activity.  Physician CreditsAccreditation Norton Healthcare is accredited by the Kentucky Medical Association to provide continuing medical education for physicians. Designation Norton Healthcare designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nursing Credits Norton Healthcare Institute for Education and Development is approved as a provider of nursing continuing professional development by the South Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. This continuing professional development activity has been approved for 0.50 ANCC CE contact hours. In order for nursing participants to obtain credits, they must claim attendance by attesting to the number of hours in attendance.   For more information related to nursing credits, contact Sally Sturgeon, DNP, RN, SANE-A, AFN-BC at (502) 446-5889 or sally.sturgeon@nortonhealthcare.org.   Resources for Additional Study/ReferencesAmerican Perspectives on Early Detection of Alzheimer's Disease in the Era of Treatment https://www.alz.org/alzheimers-dementia/facts-figures   Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care https://pubmed.ncbi.nlm.nih.gov/39068545/   Date of Original Release | Sept. 2025; Information is current as of the time of recording.  Course Termination Date | Sept. 2028 Contact Information | Center for Continuing Medical Education; (502) 446-5955 or cme@nortonhealthcare.org Also listen to Norton Healthcare's podcast Stronger After Stroke. This podcast, produced by the Norton Neuroscience Institute, discusses difficult topics, answers frequently asked questions and provides survivor stories that provide hope. Norton Healthcare, a not for profit health care system, is a leader in serving adult and pediatric patients throughout Greater Louisville, Southern Indiana, the commonwealth of Kentucky and beyond. More information about Norton Healthcare is available at NortonHealthcare.com.

Oral Arguments for the Court of Appeals for the Federal Circuit
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company

Oral Arguments for the Court of Appeals for the Federal Circuit

Play Episode Listen Later Sep 5, 2025 39:13


Teva Pharmaceuticals International GmbH v. Eli Lilly and Company

Inside the ICE House
Biotech Series: Eli Lilly Chief AI Officer Thomas Fuchs on AI's Power to Transform Pharmaceuticals

Inside the ICE House

Play Episode Listen Later Sep 4, 2025 24:30


AI is revolutionizing pharmaceuticals, moving from a side tool to a core driver of many aspects of the industry. Eli Lilly is leading the way, appointing Thomas Fuchs as its first Chief AI Officer to integrate AI across its pipeline. A NASA and Mount Sinai veteran, Fuchs is turning Lilly's data into a competitive edge. He joins Inside the ICE House to share how Lilly is building the AI-powered medicine company of the future.

ASCO Daily News
Promising New Therapies in Non-Muscle Invasive Bladder Cancer

ASCO Daily News

Play Episode Listen Later Sep 4, 2025 18:27


Dr. Sumanta (Monty) Pal and Dr. Petros Grivas discuss innovative new intravesical therapies and other recent advances in the treatment of non-muscle invasive bladder cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello and welcome. I'm Dr. Monty Pal here at the ASCO Daily News Podcast. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. And I'm really delighted to be your new host here. Today's episode is going to really sort of focus on an area near and dear to my heart, something I actually see in the clinics, and that's bladder cancer. We're specifically going to be discussing non-muscle invasive bladder cancer, which actually comprises about 75% of new cases. Now, in recent years, there's been a huge shift towards personalized bladder-preserving strategies, including innovative therapies and new agents that really are reducing reliance on more primitive techniques like radical cystectomy and radiation therapy. And I'm really excited about this new trend. And really at the forefront of this is one of my dear friends and colleagues, Dr. Petros Grivas. He's a professor in the Department of Medicine and Division of Hematology Oncology at the University of Washington. It's going to take a while to get through all these titles. He's taken on a bunch of new roles. He is medical director of the International Program, medical director of the Local and Regional Outreach Program, and also professor in the Clinical Research Division at the Fred Hutch Cancer Center. Petros, welcome to the program. Dr. Petros Grivas: Thank you so much, Monty. It's exciting for me to be here. Dr. Sumanta (Monty) Pal: Just FYI for our audience, our disclosures are available in the transcript of this episode.  We're going to get right into it, Petros. Non-muscle invasive bladder cancer, this is a really, really challenging space. We see a lot of recurrence and progression of the disease over time, about 50% to 70% of patients do have some recurrence after initial treatment, and about 30% are ultimately going to progress on to muscle-invasive or metastatic disease. Now, I will say that when you and I were in training, non-muscle invasive bladder cancer was something that was almost relegated to the domain of the urologist, right? They would use treatments such as BCG (Bacillus Calmette-Guérin) in a serial fashion. It was rare, I think, for you and I to really enter into this clinical space, but that's all changing, isn't it? I mean, can you maybe tell us about some of the new therapies, two or three that you're really excited about in this space? Dr. Petros Grivas: Monty, you're correct. Traditionally and conventionally, our dear friends and colleagues in urology have been managing patients with non-muscle invasive bladder cancer. The previous term was superficial bladder cancer. Now, it has changed, to your point, to non-muscle invasive bladder cancer. And this has to do with the staging of this entity. These tumors in superficial layers of bladder cancer, not invading the muscularis propria, the muscle layer, which makes the bladder contract for urine to be expelled. As you said, these patients have been treated traditionally with intravesical BCG, one of the oldest forms of immunotherapy that was developed back in the 1970s, and this is a big milestone of immunotherapy development. However, over the years, in the last 50 years, there were not many options for patients in whom the cancers had progression or recurrence, came back after this intravesical BCG. Many of those patients were undergoing, and many of them still may be undergoing, what we call radical cystectomy, meaning removal of the bladder and the lymph nodes around the bladder. The development of newer agents over the last several years has given the patients the option of having other intravesical therapies, intravesical meaning the delivery of drugs, medications inside the bladder, aiming to preserve the bladder, keep the bladder in place. And there are many examples of those agents. Just to give you some examples, intravesical chemotherapy, chemotherapy drugs that you and me may be giving intravenously, some of them can be given inside the bladder, intravesical installation. One example of that is a combination of gemcitabine and docetaxel. These drugs are given in sequence one after the other inside the bladder, and they have seen significant efficacy, good results, again, helping patients keeping the bladder when they can for patients with what we call BCG unresponsive non-muscle invasive bladder cancer. And again, there's criteria that the International Bladder Cancer Group and the FDA developed, how to define when BCG fails, when we have BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: And we're actually going to get into some of the FDA requirements and development pathways and so forth. What I'm really interested in hearing, and I'm sure our audience is too, are maybe some of the new intravesical treatments that are coming around. I do think it's exciting that the gemcitabine and docetaxel go into the bladder indeed, but what are some of the top new therapies? Pick two or three that you're excited about that people should be looking out for in this intravesical space. Dr. Petros Grivas: For sure, for sure. In terms of the new up-and-coming therapies, there are a couple that come to mind. One of them is called TAR-200, T-A-R 200. This agent is actually a very interesting system. It's an intravesical delivery of a chemotherapy called gemcitabine, the one that I just mentioned a few minutes ago, that is actually being delivered through what we call a pretzel, which is like a rounded [pretzel-shaped] structure working like an osmotic pump, and that is being delivered inside the bladder intravesically by urologists. And this drug is releasing, through the osmotic release mechanism, this chemotherapeutic drug, gemcitabine, inside the bladder. And this can be replaced once every 3 weeks in the beginning. And the data so far from early-phase trials are really, really promising, showing that this agent may be potentially regulatory approved down the road. So TAR-200 is something to keep in mind. And similarly, in the same context, there is a different drug that also uses the same mechanism, and this osmotic release, this pretzel, it's just encoded with a different agent. The different agent is an FGFR inhibitor, a target therapy called erdafitinib, a drug that you and me may give in patients with metastatic urothelial carcinoma if they have an FGFR3 mutation or fusion. And that drug is called TAR-210. Dr. Sumanta (Monty) Pal: And can I ask you, in that setting, do you have to have an FGFR3 mutation to receive it? Or what is the context there? Dr. Petros Grivas: So for TAR-210, TAR-2-1-0, usually there is a checking to see if there is an FGFR3 mutation or fusion. And the big question, Monty, is do we have adequate tissue, right? From a limited tissue on what we call the TURBT, right, that urologists do. And now there is a lot of development in technology, for example, urine circulating tumor DNA to try to detect these mutations in the urine to see whether the patient may be eligible for this TAR-210. Both of those agents are not FDA approved, but there are significant promising clinical trials. Dr. Sumanta (Monty) Pal: So now let's go to a rapid-fire round. Give us two more agents that you're excited about in this intravesical space. What do you think? Dr. Petros Grivas: There is another one called cretostimogene. It's a long name. Dr. Sumanta (Monty) Pal: They really make these names very easy for us, don't they? Dr. Petros Grivas: They are not Greek names, Monty, I can tell you, you know. Even my Greek language is having trouble pronouncing them. The cretostimogene, it's actually almost what we call a growth factor, a GM-CSF. The actual name of this agent is CG0070. This is a replicating mechanism where GM-CSF is replicating in cells. And this agent has shown significant results again, like the TAR-200, in BCG unresponsive non-muscle invasive bladder cancer. I would say very quickly, two agents that actually were recently approved and they're already available in clinical practice, is nadofaragene firadenovec, another long name. That's a non-replicating vector that has the gene of interferon alfa-2b that stimulates the immune system in the bladder. It's given once every 3 months. And the last one that was, as I mentioned, already FDA approved, it's an interleukin-15 superagonist. It's another long name, which is hard to pronounce, but I will give it a try. It's a drug that was recently actually approved also in the UK. The previous name was N-803. It's given together with BCG as a combination for BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: This is a huge dilemma, I think, right? Because if you're a practicing, I'm going to say urologist for the moment, I guess the challenge is how do you decide between an IL-15 superagonist? How do you decide between a pretzel-eluting agent? How do you decide between that and maybe something that's ostensibly, I'm going to guess, cheaper, like gemcitabine and docetaxel? What's sort of the current thinking amongst urologists? Dr. Petros Grivas: Multiple factors play into our account when the decision is being made. I discuss with urologists all the time. It's not an easy decision because we do not have head-to-head comparisons between those agents. As you mentioned, intravesical chemotherapy with gemcitabine and docetaxel has been used over the years and this is the lowest cost, I would say, the cheapest option with good efficacy results. Obviously, the nadofaragene firadenovec every 3 months and the interleukin-15 superagonist, N-803, plus BCG have also been approved. The question is availability of those agents, are they available? Are they reimbursed? Cost of those agents can come into play. Frequency of administration, you know, once every 3 months versus more frequent. And of course, the individual efficacy and toxicity data, preference of the patients; sometimes the provider, the urologist, may have something that they may be more familiar with. But we lack this head-to-head comparison. Of course, I want to make sure I mention that radical cystectomy may still be the option for appropriate patients. So that complicates also the decision making and has to be individualized, customized, and personalized, taking into account all those factors. And there is not one size fitting all. Dr. Sumanta (Monty) Pal: So I think we discussed five intravesical therapies. As you point out, and you know, I'm going to get some calls about this: I think I referred to radical cystectomy as being a more primitive procedure. Not true at all. I think it's something that still is, you know, a mainstay of management in this disease space. But I guess it gets even more complicated, am I right, Petros? Because now we have systemic therapies that we can actually apply in this non-muscle invasive setting for at this point, refractory disease. Can you maybe just give us a quick two-minute primer on that? Dr. Petros Grivas: Absolutely, and systemic therapies now come into play, as you said. And a classical example of that, Monty, came from the KEYNOTE-057 trial that we published about 6 years ago. This is intravenous pembrolizumab, given intravascularly, intravenously, as opposed to the previously discussed intravesical administration of agents. Pembrolizumab was tested in that KEYNOTE-057 trial and showed efficacy about, I would say, one out of five patients, about 20%, had a complete response of the tumor in the bladder in a year after starting the treatment. Again, it's hard to compare across different agents, but obviously when we give something intravenously, there is a risk of toxicity, side effects systemically, what we call immune-related adverse events. And this can also play in the decision making, right? When you have intravesical agents versus intravascular agents, there is different toxicity profiles in terms of systemic toxicity. But intravenous pembrolizumab has been an option, FDA approved, since, if I remember, it was early 2020 when this became FDA approved. There are other agents being tested in this disease, but like atezolizumab through the SWOG study that Dr. Black and Dr. Singh led, but atezolizumab is not FDA approved for this indication. Again, this is for BCG unresponsive, high-risk, non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: So maybe teach us how it works, for instance, at an expert center like the Fred Hutch. When you see a patient with non-muscle invasive bladder cancer, there's obviously the option of surgery, there's the intravesical therapies, which I imagine the urology team is still really at the helm of. But then, I guess there has to be consideration of all options. So you've got to bring up systemic therapy with agents like pembrolizumab. In that context, are you involved that early on in the conversation? Dr. Petros Grivas: That's a great discussion, Monty. Paradigm is shifting as we mentioned together. The urologists have been treating these patients and still they are the mainstay of the treaters, the managers in this disease. But medical oncologists come to play more and more, especially with the FDA approval of intravenous pembrolizumab about 5 years ago [GC1]  [KM2] . We have the concept of multidisciplinary bladder cancer clinic here at Fred Hutch and University of Washington. This happens every Tuesday morning, and we're very excited because it's a one-stop shop for the patients. We have the urologist, a medical oncologist, radiation oncologist, and experts from radiology and pathology, and we all review cases specifically with muscle-invasive bladder cancer. But every now and then, we see patients with BCG unresponsive non-muscle invasive bladder cancer. And this is where we discuss and we talk to the patient about pros and cons of all those options. And that's a classic example where medical oncologists may start to see those patients and offer their input and expertise. In addition to that, sometimes we have clinical trials, we may see these patients because there are systemic agents that may be administered in this setting. We have the SunRISe trial program that includes also a systemically administered checkpoint inhibitor. So that's another example where we see patients either in the context of multi-clinic or in individual solo clinics to counsel the patients about the pros and cons of the systemically administered agents in the context of clinical trials. Usually checkpoint inhibitors are the class of agents that are being tested in this particular scenario. Dr. Sumanta (Monty) Pal: I can see a scenario where it's really going to require this sort of deep dive, much in the way that we do for prostate cancer, for instance, where the medical oncologist is involved very early on and planning out any sort of systemic therapy component of treatment or at the very least, at least spelling out those options. I think it's going to be really interesting to see what this space looks like 5 or 10 years down the road. In closing, I wanted to go through something that I think is so different in this space, at least for the time being, and that is the paradigm for FDA approval. When you and I have our fellows in the clinics, we always say, “Look, you know, the paradigm in this disease and that disease and the other disease needs to be phase 3 randomized trials, right? Big thousand patient experiences where you're testing clinical endpoints.” That's tough in non-muscle invasive bladder cancer, right? Because thankfully, outcomes can actually be quite good, you know, in this setting, right? It's tough to actually estimate overall survival in some of these early-stage populations. Tell me what the current regulatory bar is, and this is a tough thing to do in 2 minutes or less but tell me where you see it headed. Dr. Petros Grivas: You alluded to that before, Monty, when I was giving the background and we talked about the regulatory approval. And I have to very quickly go back in time about 10 years ago because it's important for context that can help us in other disease types too. We had workshops with the FDA and the NCI with the help of the International Bladder Cancer Group and other colleagues. And we try to define a framework, what endpoints are meaningful for those patients in this disease. It was a multidisciplinary, multiple stakeholders meeting, where we tried to define what is important for patients. What are the available agents? What are the trial designs we can accept? And what are the meaningful endpoints that the regulatory agencies can accept for regulatory approval? And that was critical in that mission because it allowed us to design clinical trials, for example, single-arm trials in a disease where there was no standard of care. There was intravesical valrubicin and chemotherapy anthracycline that was approved for many years, but was not practically used in clinical practice, despite being approved, the valrubicin. And because of that, the FDA allowed these single-arm trials to happen. And obviously the endpoint was also discussed in that meeting. For example, for carcinoma in situ, complete response, clinical complete response, because the bladder remains intact in many patients, clinical complete response was a meaningful primary endpoint, also duration of response is also very important. So what is the durable clinical complete response in 1 year or 18 months is relevant. And when you have papillary tumors like Ta or T1 with CIS, for papillary tumors, event-free survival becomes one of the key endpoints and you look at it over time, for example, at 12 or 18 months, what is the event-free survival? So clinical complete response, duration of response, event-free survival, depending on the CIS presence or papillary tumors, I think these are endpoints that have allowed us to design those trials, get those agents approved.  Now, the question going forward, Monty, and we can close with that is, since now we have the embarrassment of riches, many more options available compared to where we were 6 and 7 years ago, is now the time to do randomized trials? And if we do randomized trials, which can be the control group? Which of those agents should be allowed to be part of the control group? These are ongoing discussions right now with the NCI, with other agencies, cooperative groups, trying to design those trials and move forward from here.[GC3]  Dr. Sumanta (Monty) Pal: Well, it's awesome to have you here on the program so we can get some early looks into some of these conversations. I mean, clearly, you're at the table at a lot of these discussions, Petros. So I want to thank you for sharing your insights with us today. This was just tremendous. Dr. Petros Grivas: Thank you, Monty. You know, patients in the center, I just came back from the Bladder Cancer Advocacy Network meeting in Washington, D.C., and we discussed all those questions, the topics you very eloquently mentioned and asked me today, and patients gave us great feedback and patients guide us in that effort. Thank you so, so much for having me and congratulations for the amazing podcast you're doing. Dr. Sumanta (Monty) Pal: Oh, cheers, Petros, thanks so much.  And thank you to the listeners who joined us today. If you really like the insights that you heard on this ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:      Dr. Sumanta (Monty) Pal  @montypal  Dr. Petros Grivas @PGrivasMDPhD   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Sumanta (Monty) Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Petros Grivas: Consulting or Advisory Role: Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Strata Oncology, Abbvie, Bicycle Therapeutics Replimune, Daiichi Sankyo, Foundation Medicine, Bicycle Therapeutics, Eli Lilly, Urogen Pharma, Tyra Biosciences Research Funding (Inst.): Bristol-Myers Squibb, Merck, EMD Serono, Gilead Sciences, Acrivon Therapeutics, ALX Oncology, ALX Oncology, Genentech Travel, Accommodations, Expenses: Gilead Sciences

Irish Tech News Audio Articles
Starcircle's Supernova rolls out the red carpet with "Hiring at the Movies" themed talent acquisition conference

Irish Tech News Audio Articles

Play Episode Listen Later Sep 4, 2025 3:25


In a world of scarce talent and shifting work, one conference dares to reimagine how we cast our teams. On Friday, 5 September 2025, Starcircle, the hiring platform that helps companies solve hiring challenges with AI and on-demand expertise, premieres Supernova 2025: Hiring at the Movies at The Cameo Cinema, The Montenotte Hotel, Cork. The latest SOLAS survey revealed 47% of hard-to-fill roles were rated "very" or "too" difficult, and 64% required salary increases to seal the deal. Inspired by these real events, Supernova is flipping the script, taking hiring teams from today's recruiting horror story to a rom-com where they fall back in love with talent acquisition. Under the theme "Hiring at the Movies," Supernova 2025 connects the craft of film casting with the future of talent acquisition. Professionals from Eli Lilly, Workhuman, OpenText and many others, will gather to discuss what's next for hiring and the nature of work, along with real steps leaders can take now. The star-studded line-up includes two of Ireland's best-known casting directors, Maureen Hughes and Louise Kiely. They will unpack the craft of spotting potential, building chemistry, and making brave choices, all critical skills for any hiring team. They're joined by keynote speaker Kevin Wheeler, whose vision of a tech-powered future may sound stranger than fiction, but is quickly becoming a reality. The machines haven't taken over just yet though, as Larry Kelly explores the power of human imagination at work and why creativity is a decisive advantage in an AI-shaped future. "Supernova is where we zoom out to see what's coming and zoom in on what to do on Monday," said James Galvin, CEO at Starcircle. "Linking hiring to the world of film makes it simple; great outcomes start with a strong vision, a bold brief, and the imagination to see talent others miss." Galvin continues, "Supernova blends big-picture thinking with practical guidance. Since our first conference in 2022, we've brought together leading experts from around the world to share their playbooks and help organisations navigate the ever-changing landscape. This year promises to be our best event yet, and you won't find a talent event like this anywhere else in the world." Supernova is invite-only. For more information and to register your interest, visit here or contact events@starcircle.com See more stories here. More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to discuss. Irish Tech News have a range of services available to help promote your business. Why not drop us a line at Info@IrishTechNews.ie now to find out more about how we can help you reach our audience. You can also find and follow us on Twitter, LinkedIn, Facebook, Instagram, TikTok and Snapchat.

Pharma and BioTech Daily
Pharma and Biotech Daily: Navigating Innovation and Partnerships in Turbulent Times

Pharma and BioTech Daily

Play Episode Listen Later Sep 3, 2025 1:44


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Novo Nordisk's drug Wegovy has successfully reduced cardiovascular risk by 57% compared to tirzepatide. Eli Lilly has terminated two mid-stage trials for a second obesity asset, while Vertex Pharmaceuticals and Enlaza Therapeutics have formed a potential $2 billion partnership to develop drugs for autoimmune diseases. Biogen and Eisai have received FDA approval for the subcutaneous maintenance formulation of Leqvembi. Arrowhead Pharmaceuticals has secured a commitment of up to $2 billion from Novartis for an siRNA Parkinson's program. The FDA's new radiopharma guidance is expected to accelerate the space, and Teva has launched the first generic version of Novo Nordisk's obesity drug Saxenda. The pharmaceutical industry is navigating uncertainty during turbulent times, with companies focusing on innovation and new partnerships to drive progress.The FDA has issued new radiopharma guidance, which former FDA Commissioner Stephen Hahn believes is crucial for cancer therapy. Despite recent investments in radiopharmaceutical therapeutics by big pharma, the FDA's approval of updated COVID-19 vaccines with restrictions contradicts the medical freedom promised by health secretary Robert F. Kennedy Jr. Rare diseases secured four FDA firsts in August, including a win for Novo Nordisk's glp-1 drug WeGovy. Investment in new ALS therapies signals progress after setbacks, with new biotechs and collaborative initiatives showing promise at Bio2025. Other news includes the closure of Appia, Senate summons of Kennedy, updates on COVID-19 vaccines, and Lilly's obesity pill heading to the FDA. Thank you for listening to Pharma and Biotech daily.

Market Mondays
MM #274: Stocks That Benefit From Trump, Nvidia's Top Risk, Ozempic $2B Lawsuits, & September Market Strategy

Market Mondays

Play Episode Listen Later Sep 2, 2025 126:09


This week's Market Mondays is packed with high-level investing questions and timely market insights. We break down which five companies could thrive under a Trump administration, discuss whether Nvidia has a revenue concentration problem, and share advice for investors earning $50K–$100K per year on how to balance stocks, bonds, and real estate. We also dive into how to calculate intrinsic value—Ben Graham style, Warren Buffett style, or your own strategy—and what to actually do when your 5–10 year holding period is up.We also explore September 2025 market outlooks, Morgan Stanley's latest stock picks, and Alibaba's surprising surge after reports it may challenge Nvidia in the AI chip space. From fixed income products like MSTY and NVDY to the crypto markets hovering at key Fibonacci levels, we break down what's holding Bitcoin and ETH back, and how investors should be positioning in a historically tricky month. Plus, we play a round of “Don't Love, Marry, Kill” with Charter Communications, Hormel Foods, and Keurig Dr Pepper.Finally, we dig into the brewing legal storm around Novo Nordisk and Eli Lilly, facing over 2,000 lawsuits tied to Ozempic and similar drugs, with potential liability estimated in the billions. Is this the “death of Novo Nordisk,” or just another chapter in the evolving GLP-1 drug story? Tune in for sharp analysis, real strategies, and answers to the questions you've been asking all week.#MarketMondays #Investing #Stocks #Crypto #AI #Trump #Nvidia #Ozempic #WealthBuilding #FinancialLiteracyOur Sponsors:* Check out PNC Bank: https://www.pnc.com* Check out Square: https://square.com/go/eylSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Wake Up to Money
Drug costs and tariffs lost?

Wake Up to Money

Play Episode Listen Later Sep 1, 2025 52:15


Will Bain has the latest after an another eventful weekend for trade and geopolitics.Meanwhile, closer to home, Eli Lilly's weight loss drug makes its way back onto shelves ... only at a much higher price. We hear from pharmacy that's having to navigate the hike.

On The Pen: The Weekly Dose
Zepbound Compound Lawsuit Update: Eli Lilly Vs Mochi

On The Pen: The Weekly Dose

Play Episode Listen Later Aug 30, 2025 66:26


Visit our links: https://linktr.ee/manonthemounjaro

Alles auf Aktien
KI killt Einsteiger-Jobs und die 7 nächsten Biotech-Blockbuster

Alles auf Aktien

Play Episode Listen Later Aug 29, 2025 20:45


In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über KI-Optimismus bei Dell, eine neue Toniebox-Euphorie in Kinderzimmern und einen Analysten-Push für Siemens. Außerdem geht es um Ulta Beauty, Marvell, Gap, Amazon, Microsoft, Meta, Spotify, IBM, Alphabet, Bristol Myers Squibb, Argenx, Legend Biotech, Summit Therapeutics, Denali Therapeutics, Intellia, Regeneron, Immunocore, Viking Therapeutics, Novo Nordisk und Eli Lilly. Die Tickets zum Finance Summit am 17. September bekommt ihr 40 Euro günstiger – aber nur mit dem exklusiven Code AAA2025, der ihr unter dem folgenden Link eingeben müsst: https://veranstaltung.businessinsider.de/BN5aLV Außerdem könnt ihr unter diesem Link euer Depot hochladen – und mit etwas Glück wird kein Geringerer als Christian W. Röhl euer Depot beim Summit checken und optimieren. https://form.jotform.com/Product_Unit/formular-finance-summit-depot-check Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

The I Love CVille Show With Jerry Miller!
AstraZeneca Building Multi-Billion Dollar HQ In AlbCo; Eli Lilly Doing The Same In Goochland

The I Love CVille Show With Jerry Miller!

Play Episode Listen Later Aug 28, 2025 61:51


The I Love CVille Show headlines: AstraZeneca Building Multi-Billion Dollar HQ In AlbCo Eli Lilly Building Multi-Billion Dollar HQ In Goochland 2 Publicly Traded Co's Spending Billions In CVille Area Home Depot Opens Today In Albemarle County How Can Area Small Business Appeal To GenZ Labor? Coastal Carolina At UVA (-11.5), 6PM, Sat, ACCN New Show W/ Jeff Gaffney & Dr. Wayne Frye, 9/1, 1015am Exec Offices For Rent ($350 – $2000), Contact Jerry Read Viewer & Listener Comments Live On-Air The I Love CVille Show airs live Monday – Friday from 12:30 pm – 1:30 pm on The I Love CVille Network. Watch and listen to The I Love CVille Show on Facebook, Instagram, Twitter, LinkedIn, iTunes, Apple Podcast, YouTube, Spotify, Fountain, Amazon Music, Audible, Rumble and iLoveCVille.com.

Becker Group C-Suite Reports Business of Private Equity
16 Stories We Are Following Today 8-27-25

Becker Group C-Suite Reports Business of Private Equity

Play Episode Listen Later Aug 27, 2025 3:48


In this episode, Scott Becker covers 16 business and market updates, including NVIDIA earnings, Eli Lilly's weight loss pill, EchoStar's deal with AT&T, and more.

Great Women in Compliance
Navigating Risk, Culture, and Compliance with Teri Cotton Santos

Great Women in Compliance

Play Episode Listen Later Aug 27, 2025 27:34


✨ New Episode Alert! ✨ On this special episode of #GWIC, guest host Ellen Hunt talks with the incredible Teri Cotton Santos, Chief Compliance Officer at Phillips 66. Teri shares her inspiring journey—from serving as General Counsel in Asia at Eli Lilly to leading compliance at HF Sinclair, and now shaping the culture of ethics and compliance at Phillips 66.

Combinate Podcast - Med Device and Pharma
203 - Drug Delivery, Platforms, IP Battles, Supply Chain Risks with Jim Collins

Combinate Podcast - Med Device and Pharma

Play Episode Listen Later Aug 27, 2025 45:50


In this episode of Let's Combinate, Subhi Saadeh sits down with Jim Collins, a leader in drug delivery with over 30 years of experience at Eli Lilly, Sanofi, and now as an advisor and board member. Jim shares the history of combination products before the term even existed, from insulin pens in the 1990s to modern platforms and on-body injectors. We cover IP battles that reshaped the industry, supply chain risks that pharma still underestimates, and why platform strategy is one of the most important decisions a company can make today.Timestamps:00:00 – Introduction & Guest Welcome02:00 – Building Lilly's device organization and launching insulin pens06:00 – Early “wild west” days of drug delivery vs. today's structure07:00 – Intellectual property as a competitive weapon10:30 – How Lilly, Novo, and Sanofi shaped the IP landscape13:00 – Device differentiation in the generic space17:00 – Portfolio vs. molecule decisions in platform strategy20:00 – Three reasons to develop your own platform23:00 – Supply chain risk and geopolitical considerations26:00 – Black Swan risks and lessons for pharma companies28:00 – Strategic suppliers vs. transactional vendors33:00 – Drug-device integration inside companies37:00 – Building organizational capability and governance38:00 – Future trends: large volume autoinjectors and connected devices43:00 – Impact of tariffs and supply chain positioning45:00 – Where to find Jim CollinsGuest Bio:Jim Collins is a veteran of the drug delivery field with more than 30 years of leadership experience. At Eli Lilly, he built and led the device organization, overseeing the launch of insulin pens, the Forteo Pen, and the Trulicity platform. Later, at Sanofi, he led drug delivery innovation and platform development, including devices for Dupixent. Today, Jim serves as a board member for Enable Injections and advises startups, helping the next generation of innovators navigate IP, supply chain, and platform strategy.Subhi Bio:Subhi Saadeh is a Quality Professional and host of Let's Combinate. With a background in Quality, Manufacturing Operations, and R&D, he has worked in large medical device and pharma organizations to support the development and launch of hardware devices, disposable devices, and combination products for vaccines, generics, and biologics. Subhi serves as International Committee Chair for the Combination Products Coalition (CPC), as a member of ASTM Committee E55, and previously on AAMI's Combination Products Committee. For questions, inquiries, or suggestions, visit letscombinate.com or connect on LinkedIn.

Becker Group Business Strategy 15 Minute Podcast
16 Stories We Are Following Today 8-27-25

Becker Group Business Strategy 15 Minute Podcast

Play Episode Listen Later Aug 27, 2025 3:48


In this episode, Scott Becker covers 16 business and market updates, including NVIDIA earnings, Eli Lilly's weight loss pill, EchoStar's deal with AT&T, and more.

OHNE AKTIEN WIRD SCHWER - Tägliche Börsen-News
“Heico-Chance bei Lufthansa” - Trump feuert, Eli Lilly steigt & Parker Hannifin

OHNE AKTIEN WIRD SCHWER - Tägliche Börsen-News

Play Episode Listen Later Aug 27, 2025 13:58


Erfahre hier mehr über unseren Partner Scalable Capital - dem Broker mit Flatrate und Zinsen. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Der Kalender zum Podcast? Jetzt kaufen.  Trump mag keine Cracker-Barrel-Veränderung und will FED-Gouverneurin feuern. Darf er so? Frankreichs Regierung steht vor dem aus und zieht die Märkte runter. Mercedes verkauft Nissan. EssilorLuxottica kauft Nikon. Echostar steigt 70%. Eli Lilly hat Pille. Parker Hannifin (WKN: 855950) kennt fast keiner, ist aber 100 Mrd. $ schwer und stellt wichtige Bauteile her, ohne die moderne Fabriken und Flugzeuge stillstehen würden. Lufthansa (WKN: 823212) gehören 20% an der boomenden Flugzeugsparte von Heico (WKN: 889997). Und hat auch noch andere Asse im Ärmel. Diesen Podcast vom 27.08.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

BioSpace
Lilly's Obesity Pill Heads to the FDA, AbbVie Bets on Psychedelics, HHS Unveils More Change

BioSpace

Play Episode Listen Later Aug 27, 2025 22:40


Eli Lilly posted data Tuesday from a second Phase III trial of its oral weight loss therapy orforglipron, providing the company with all it needs to head to the FDA with a new drug application. For more in-depth discussion on the oral weight-loss space, check out a special episode of The Weekly. And stay tuned to BioSpace for more unique coverage of this market as we learn which investigational assets will make it across the regulatory finish line and which will join the weight-loss wasteland. On the business side of biopharma, AbbVie turned back to neuropsychiatric therapies this week, acquiring partner Gilgamesh Pharmaceuticals' lead depression candidate for $1.2 billion. The deal is a display of resilience for AbbVie in the neuropsychiatric space as well, after the stunning failure last November of schizophrenia asset emraclidine—picked up in its nearly $9 billion acquisition of Cerevel Therapeutics. And is the cooler late summer weather thawing the IPO market? Neuropsych-focused LB Pharma revealed in an SEC filing on Friday that it plans to take the plunge, ending a six-month stalemate in biotech IPOs.  Finally, the Department of Health and Human Services (HHS) has been busy this past week. On Monday, the CDC named Retsef Levi—a known vaccine critic—to head the agency's COVID-19 immunization working group, just as reports surfaced that the Trump administration could be “within months” of banning the COVID-19 vaccine in the U.S. Meanwhile, the FDA issued new draft guidance for cancer drug developers that prioritizes the use of survival data, and the agency began publishing drug-related adverse event reports daily.   HHS itself has also been the subject of recent headlines, announcing that it will no longer recognize employee unions, and last week, hundreds of HHS staffers penned an open letter calling on Secretary Kennedy to tone down what they called “dangerous and deceitful statements” that have fostered distrust against federal health workers, exposing them to physical harm. This followed the Aug. 8 shooting at CDC headquarters in Atlanta.   Finally, multinational pharmaceutical companies spent more than $48 billion on partnerships with China in the first half of 2025 alone, according to a new report from IQVIA—more than in all of 2024.  

Oprah's Weight Loss Dilemma: The Ozempic
Ozempic Price Cut and Oprah's Weight Loss Journey Spark Nationwide Conversation About GLP-1 Medications

Oprah's Weight Loss Dilemma: The Ozempic

Play Episode Listen Later Aug 27, 2025 4:33 Transcription Available


Ozempic has dominated headlines again this week as Novo Nordisk announced a major price cut, making the diabetes drug available for 499 dollars per month to eligible cash-paying patients in the United States for the first time through their NovoCare pharmacy program and in partnership with telehealth provider GoodRx. This move follows similar pricing for Wegovy, a sister drug prescribed primarily for weight loss, and responds to mounting public and political pressure to reduce drug costs in the US, which have traditionally far outpaced those in other countries. The rapid expansion of access has sparked renewed debate on the cultural and medical impact of GLP-1 drugs, with product demand and public interest remaining extremely high.In the same news cycle, Oprah Winfrey once again became a focal point of national conversation about weight loss and Ozempic. Recent photos posted from her vacation in Italy, where she was seen truffle hunting, have drawn widespread notice for her noticeably slimmer figure. While the food adventure was part of the public narrative, much of the commentary was focused on Oprah's dramatic transformation. Earlier this year on her podcast, Oprah spoke candidly about her experience with so-called GLP-1 medications. She shared that after starting on the medicine, which functions by suppressing appetite, she began to understand how differently people can experience hunger. For years, she admits, she attributed thinness to willpower, assuming that some people simply had better self-control around food. The drug shifted her perspective, making her realize the powerful biological factors at play and how GLP-1 drugs can create a level playing field for those with obesity, a condition the talk show icon now insists is a disease of the brain, not a failure of character.Oprah's public acknowledgment of using weight loss medication was itself notable, given the intense stigma and the climate of secrecy around pharmaceutical weight loss among celebrities. She described feeling "relief," "redemption," and gratitude that she could finally manage chronic weight struggles with a tool that's medically approved. Despite having initially resisted the idea, citing a belief that using drugs was the “easy way out,” Oprah has since changed her position and has called for an end to self-blame and societal shaming. In her words, shame has been replaced by a sense of liberation, both from her own self-judgment and from external criticism. She no longer sees the use of weight loss drugs as something to be hidden or ridiculed.Medical experts weighing in this week have reiterated that Ozempic and other GLP-1 medicines do produce significant weight loss and improvements in cholesterol and triglyceride levels as long as patients continue taking them. Ziyad Al-Aly, chief of research at the Veterans Affairs St. Louis Healthcare System, emphasizes that the drugs enhance not just weight management but overall metabolic health. However, there are crucial caveats: studies published this week in Diabetes Obesity and Metabolism confirm that stopping GLP-1 medication typically results in regaining as much as two-thirds of the lost weight and a reversal of most health benefits. This so-called rebound effect has caused concern among physicians, who urge patients to understand the drugs are best considered a long-term therapy rather than a short-term fix.As demand spikes, news of rare but concerning adverse effects, such as potential vision changes, has kept the safety discussion alive, though current expert consensus is that for most people prescribed these medications appropriately, the benefits outweigh the risks. Meanwhile, Novo Nordisk and other drug makers continue racing to expand access through direct pharmacy programs, with Eli Lilly also announcing price reductions and new supply chain solutions for its own competing drug Zepbound.On social media and in mainstream culture, public acceptance of GLP-1 treatments appears to be moving quickly, especially with high-profile advocates like Winfrey openly discussing their use and encouraging an end to the blame game around obesity. As Oprah underscored in her latest episodes, the real shift is away from stigma and toward a greater understanding of the science of obesity and the power of new medications to address it as a medical condition, not a moral failing.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

CNBC's
Trump's Fed Fire Fight… And Eli Lilly's Weight Loss Win 8/26/25

CNBC's "Fast Money"

Play Episode Listen Later Aug 26, 2025 43:19


President Trump looking to remove Fed Governor Lisa Cook after allegations of mortgage fraud. The battle brewing at the central bank, and how she's fighting back. Plus A major win in Eli Lilly's weight loss ambitions. The pill trial results pushing that drug towards approval, and what it means for the obesity drug wars. Fast Money Disclaimer 

Squawk on the Street
SOTS 2nd Hour: Trump-Lisa Cook Conflict, Jefferies' David Zervos, & LIVE: Interactive Brokers' Thomas Peterffy 8/26/25

Squawk on the Street

Play Episode Listen Later Aug 26, 2025 42:55


President Trump saying he's firing Fed Governor Lisa Cook; Lisa Cook firing back that he doesn't have the authority – and she's not stepping down. Carl Quintanilla, David Faber, and Michael Santoli broke down the latest developments in the story, before talking potential fallout with Jefferies Strategist and Fed Chair contender David Zervos. Plus: the outlook for stocks amid the volatility – and better-than-expected consumer confidence data… Nuveen's Chief Investment Officer joined the team with her take on the action.  Also in focus: a number of market movers in early trading… Interactive Brokers shares gaining on news it's joining the S&P 500: Chairman & Founder Thomas Peterffy discussed where he sees growth ahead in the business – and broader markets. Eli Lilly also in the green on new obesity pill data: hear more on how to play shares with an analyst forecasting big gains ahead. Plus: a deep-dive on how AI is impacting a big part of the finance industry – excel spreadsheets. Squawk on the Street Disclaimer

Squawk on the Street
Cramer's Morning Take: Eli Lilly 8/26/25

Squawk on the Street

Play Episode Listen Later Aug 26, 2025 3:32


Cramer says this pharmaceutical giant's stock can climb. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market's biggest headlines. Signup here: cnbc.com/morningtake CNBC Investing Club Disclaimer

Squawk on the Street
Trump-Cook Firing Showdown and the Fed, Lutnick on Defense Stakes, AT&T-EchoStar $23B Spectrum deal 8/26/25

Squawk on the Street

Play Episode Listen Later Aug 26, 2025 42:52


Carl Quintanilla, Jim Cramer and David Faber engaged in a wide-ranging discussion about the White House taking its attacks on the Fed to an unprecedented level. President Trump said he fired Fed Governor Lisa Cook amid mortgage fraud allegations, but Cook responded by saying Trump has no authority to remove her and that she is not resigning. What might it all mean for Fed independence and the markets? Also in focus: What Commerce Secretary Lutnick told CNBC about the U.S. government potentially taking stakes in defense contractors, EchoStar soars on its $23 billion spectrum deal with AT&T, Eli Lilly obesity pill trial results, Nvidia earnings one day away.Squawk on the Street Disclaimer

Halftime Report
The Road Ahead for Stocks 8/26/25

Halftime Report

Play Episode Listen Later Aug 26, 2025 44:10


Scott Wapner and the Investment Committee debate the markets, the future of the Fed, and some new reporting on Apple's AI ambitions. The experts react to stock moves in Netflix, Uber, Eli Lilly, AT&T, and Oklo. The desk talks about the state of the restaurant trade. Josh Brown updates the viewers on his “Best Stocks in the Market.” The Setup is on Ulta Beauty ahead of earnings later this week. Investment Committee Disclosures

Rob Black and Your Money - Radio
Bracing For Nvidia Earnings Stocks Are Steady

Rob Black and Your Money - Radio

Play Episode Listen Later Aug 26, 2025 37:29


Stocks were relatively unchanged as Wall Street awaits quarterly figures from chip giant Nvidia, No more shots: Eli Lilly stock pops after weight-loss pill meets targets in diabetes trial, More on Pints and Portfolios with Rob Black and a Certified Financial Planner from EP Wealth Advisors on Saturday September 6th from 12 noon to 2pm in Pleasant Hill 

The Investing Podcast
Lisa "The Fraudster" Cook is Fired | August 26, 2025 – Morning Market Briefing

The Investing Podcast

Play Episode Listen Later Aug 26, 2025 24:38


Andrew and Tom discuss Trump firing Lisa Cook, Eli Lilly completing late-stage trial of Oforgilpron, and EssilorLuxxotica reportedly taking a 20% stake in Nikon. We got a new mixer. If the sound isn't great, please let me know. Still figuring it out. For information on how to join the Zoom calls live each morning at 8:30 EST, visit:https://www.narwhal.com/blog/daily-market-briefingsPlease see disclosures:https://www.narwhal.com/disclosure

On The Pen: The Weekly Dose
Eli Lilly VS Mochi Update + Big Lilly Orforglipron Secret Revealed

On The Pen: The Weekly Dose

Play Episode Listen Later Aug 26, 2025 36:00


Links referenced in podcast: https://linktr.ee/manonthemounjaro

Noticiero Univision
Nueva píldora para perder peso

Noticiero Univision

Play Episode Listen Later Aug 26, 2025 21:24


La farmacéutica Eli Lilly concluyó un estudio clínico con buenos resultados y promete una nueva píldora diaria para perder peso con la misma eficacia de las inyecciones semanales pero sin sus desventajas. Al parecer solo estaría pendiente la aprobación de la FDA. En otras noticias: Un inmigrante hispano detenido en un centro de detención de Georgia intentó quitarse la vida desesperado tras dos meses sin poder ver ni a su esposa, ni a sus hijos.La administración Trump está lista para deportar a Kilmar Ábrego García a Uganda. En el país africano las reacciones no se han hecho esperar.El presidente Trump aseguró que despidió a una gobernadora de la reserva federal: Lisa D. Cook, por supuesto fraude. Un juez federal desestimó la demanda del gobierno Trump contra los 15 jueces federales de Maryland que prohibieron deportar a inmigrantes durante al menos 48 horas después de su detención. 

Rob Black & Your Money
Bracing For Nvidia Earnings Stocks Are Steady

Rob Black & Your Money

Play Episode Listen Later Aug 26, 2025 37:29


Stocks were relatively unchanged as Wall Street awaits quarterly figures from chip giant Nvidia, No more shots: Eli Lilly stock pops after weight-loss pill meets targets in diabetes trial, More on Pints and Portfolios with Rob Black and a Certified Financial Planner from EP Wealth Advisors on Saturday September 6th from 12 noon to 2pm in Pleasant Hill See omnystudio.com/listener for privacy information.

The Rundown
White House Weighs Stakes in Defense Stocks, Eli Lilly Clears Hurdle for Weight-Loss Pill

The Rundown

Play Episode Listen Later Aug 26, 2025 9:33


Stock market update for August 26, 2025.This video is for informational purposes only and reflects the views of the host and guest, not Public Holdings or its subsidiaries. Mentions of assets are not recommendations. Investing involves risk, including loss. Past performance does not guarantee future results. For full disclosures, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Public.com/disclosures⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

Pharma and BioTech Daily
Pharma and Biotech Daily: AbbVie Acquires Gilgamesh, IPO Stalemate Ends, Oral Obesity Therapies Disappoint

Pharma and BioTech Daily

Play Episode Listen Later Aug 26, 2025 1:16


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.AbbVie has acquired Gilgamesh Pharmaceuticals for $1.2 billion, focusing on neurology and depression treatments. This move follows AbbVie's previous failure with Emraclidine in schizophrenia treatment. The biotech industry's IPO stalemate appears to be ending, with Lb Pharma planning an IPO to fund a phase III-ready schizophrenia asset. The FDA has pulled Valneva's chikungunya shot from the market due to safety concerns, and several obesity drugs have failed to make it to market. Meanwhile, Arnatar is working on advancing RNA therapies beyond silencing.In other news, the disappointment of oral obesity therapies is discussed, with Novo emerging as a leader in the field. Trials for Eli Lilly's Orforglipron and Viking Therapeutics' VK2735 were underwhelming, leading to increased interest in weight loss pills in low- and middle-income countries. Capricor Therapeutics plans to fight FDA rejection of its DMD cardiomyopathy treatment, while a study in JAMA contradicts claims of corruption in vaccine advisory committees. Updates on cancer, cell and gene therapy are also provided.Stay tuned for more updates and feel free to suggest topics for future coverage.

NY to ZH Täglich: Börse & Wirtschaft aktuell
Cook Beben durch Trump | New York to Zürich Täglich

NY to ZH Täglich: Börse & Wirtschaft aktuell

Play Episode Listen Later Aug 26, 2025 16:42


Die Wall Street zeigte sich am Dienstag weitgehend richtungslos. Nach der Entlassung von Fed-Gouverneurin Lisa Cook durch Präsident Trump verharrten Dow Jones, S&P 500 und Nasdaq um die Nulllinie. Langfristige Renditen stiegen, während kurzfristige Zinsen fielen – ein Signal für die Befürchtung, dass eine politisierte Fed Inflation weniger im Blick hat. Im Fokus stehen die Quartalszahlen von Nvidia am Mittwochabend. Unternehmensseitig rückten auch AMD in den Blick – nach einer Hochstufung durch Truist, die auf starkes Interesse von Hyperscalern verweist – sowie IBM, das neue KI-Dienste ankündigte. Eli Lilly legte nach positiven Studiendaten zur Abnehmpille Orforglipron zu. AT&T gab bekannt, den Netzausbau schneller als geplant voranzutreiben. Zusätzlich stützte das US-Verbrauchervertrauen die Kurse leicht: Der Index stieg im August auf 97,4 Punkte und übertraf damit die Erwartungen. Abonniere den Podcast, um keine Folge zu verpassen! ____ Folge uns, um auf dem Laufenden zu bleiben: • X: http://fal.cn/SQtwitter • LinkedIn: http://fal.cn/SQlinkedin • Instagram: http://fal.cn/SQInstagram

BioSpace
Oral Weight-Loss Race Heats Up as New Data From Lilly, Viking Reset Expectations

BioSpace

Play Episode Listen Later Aug 26, 2025 17:54


Oral therapies are projected to account for 25% of the anti-obesity medication market by 2030—but first returns have largely disappointed. This month, shares of both Eli Lilly and Viking Therapeutics took a hit as investors reacted negatively to highly anticipated Phase III and Phase II results for their respective candidates.While the 9.1% placebo-adjusted weight loss generated by Lilly's orforglipron over 72 weeks was an efficacy miss by most analyst accounts, tolerability tripped up oral VK2735's otherwise best-case efficacy scenario—10.9% weight loss after just 13 weeks. These murky results have left observers wondering, just how game-changing these pills will be and which ones will be most effective?In such a hot space, Lilly's and Viking's results—which follow Novo Nordisk's new drug application for an oral form of Wegovy in May—are only the tip of the iceberg. Stay tuned to BioSpace for further in-depth coverage of the space as we learn which investigational assets will make it across the regulatory finish line and which will join the weight-loss wasteland.

Daybreak
The price drop in weight-loss drugs Indian pharma can't handle

Daybreak

Play Episode Listen Later Aug 25, 2025 10:06


Even though GLP-1 drugs have helped nearly 20 million people shed weight across the world since 2021, Indians had to wait until 2025 to get in on the action legally.To be fair, the country wasn't entirely in the dark. Semaglutide—the molecule behind pharma giant Novo Nordisk's blockbuster drugs Ozempic and Wegovy—was already available for diabetes treatment. But this March, Eli Lilly's Mounjaro (which uses a different molecule, tirzepatide) entered the market. In July, Wegovy arrived. And suddenly, India went from “we know GLP-1” to “we want the skinny shot”.Since then, the GLP-1 market in India—across diabetes and weight loss—has grown from Rs 531 crore to Rs 628 crore. And now, depending on the vantage point, things are about to get much bigger. And much cheaper.And naturally, pretty much every major Pharma major wants in on the action. Tune in. Do you work in IT? Take our surveyWant to join The Ken's team? Fill this form. 

The Top Line
Big Pharma bounces back in Q2

The Top Line

Play Episode Listen Later Aug 22, 2025 14:48


After many U.S. biopharma companies posted sales declines in the first quarter, the domestic pharma industry largely bounced back to growth in the second quarter. In this episode of "The Top Line," Fierce Pharma's Eric Sagonowsky and Kevin Dunleavy break down the numbers behind the industry’s second-quarter performance. Among U.S. pharma heavyweights, J&J, AbbVie, Pfizer, Regeneron, Bristol Myers Squibb and Biogen each eked out gains this past quarter. Their results varied, with individual stories worth highlighting at each of these major companies. Beyond earnings, Sagonowsky and Dunleavy also discuss the growing competition in diabetes and obesity treatments between Eli Lilly and Novo Nordisk, as well as Merck’s rising financial reliance on its blockbuster cancer drug Keytruda, among other topics. To learn more about the topics in this episode: Several US pharma giants stage Q2 sales turnaround after subpar results earlier in year The battle of the obesity drug heavyweights 7 top pharmas posted revenue declines in Q1. The common thread? All are US firms Biopharma briefing: Q1 trends, gene therapy updates and ASCO preview See omnystudio.com/listener for privacy information.

This Week in Google (MP3)
IM 833: The Most Popluar S3 Bucket Ever - AI Slop, Clankers, and Shrimp

This Week in Google (MP3)

Play Episode Listen Later Aug 21, 2025


AI data wars push Reddit to block the Wayback Machine China Launches Three-Day Robot Olympics Featuring Football and Table Tennis US government agency drops Grok after MechaHitler backlash, report says Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines The AI Was Fed Sloppy Code. It Turned Into Something Evil. | Quanta Magazine AI data centers made Americans' electricity bills 30% higher Sam Altman says 'yes,' AI is in a bubble Is the A.I. Sell-off the Start of Something Bigger? Thousands of Grok chats are now searchable on Google Opinion | Amy Klobuchar: I Knew A.I. Deepfakes Were a Problem. Then I Saw One of Myself. 2,178 Occult Books Now Digitized & Put Online, Thanks to the Ritman Library and Da Vinci Code Author Dan Brown Pluralistic: "Privacy preserving age verification" is bullshit (14 Aug 2025) How to use "skibidi" and other new slang added to Cambridge Dictionary YouTube Is Making a Play to Host the Oscars Leobait: Resisting AI Solutionism through Workplace Collective Action So ... is AI writing any good? Project Indigo We used AI to analyse three cities. It's true: we now walk more quickly and socialise less Hosts: Leo Laporte, Jeff Jarvis, and Paris Martineau Guest: Rich Skrenta Download or subscribe to Intelligent Machines at https://twit.tv/shows/intelligent-machines. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: pantheon.io helixsleep.com/twit

All TWiT.tv Shows (MP3)
Intelligent Machines 833: The Most Popular S3 Bucket Ever

All TWiT.tv Shows (MP3)

Play Episode Listen Later Aug 21, 2025 188:08 Transcription Available


AI data wars push Reddit to block the Wayback Machine China Launches Three-Day Robot Olympics Featuring Football and Table Tennis US government agency drops Grok after MechaHitler backlash, report says Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines The AI Was Fed Sloppy Code. It Turned Into Something Evil. | Quanta Magazine AI data centers made Americans' electricity bills 30% higher Sam Altman says 'yes,' AI is in a bubble Is the A.I. Sell-off the Start of Something Bigger? Thousands of Grok chats are now searchable on Google Opinion | Amy Klobuchar: I Knew A.I. Deepfakes Were a Problem. Then I Saw One of Myself. 2,178 Occult Books Now Digitized & Put Online, Thanks to the Ritman Library and Da Vinci Code Author Dan Brown Pluralistic: "Privacy preserving age verification" is bullshit (14 Aug 2025) How to use "skibidi" and other new slang added to Cambridge Dictionary YouTube Is Making a Play to Host the Oscars Leobait: Resisting AI Solutionism through Workplace Collective Action So ... is AI writing any good? Project Indigo We used AI to analyse three cities. It's true: we now walk more quickly and socialise less Hosts: Leo Laporte, Jeff Jarvis, and Paris Martineau Guest: Rich Skrenta Download or subscribe to Intelligent Machines at https://twit.tv/shows/intelligent-machines. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: pantheon.io helixsleep.com/twit

Radio Leo (Audio)
Intelligent Machines 833: The Most Popular S3 Bucket Ever

Radio Leo (Audio)

Play Episode Listen Later Aug 21, 2025 188:08 Transcription Available


AI data wars push Reddit to block the Wayback Machine China Launches Three-Day Robot Olympics Featuring Football and Table Tennis US government agency drops Grok after MechaHitler backlash, report says Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines The AI Was Fed Sloppy Code. It Turned Into Something Evil. | Quanta Magazine AI data centers made Americans' electricity bills 30% higher Sam Altman says 'yes,' AI is in a bubble Is the A.I. Sell-off the Start of Something Bigger? Thousands of Grok chats are now searchable on Google Opinion | Amy Klobuchar: I Knew A.I. Deepfakes Were a Problem. Then I Saw One of Myself. 2,178 Occult Books Now Digitized & Put Online, Thanks to the Ritman Library and Da Vinci Code Author Dan Brown Pluralistic: "Privacy preserving age verification" is bullshit (14 Aug 2025) How to use "skibidi" and other new slang added to Cambridge Dictionary YouTube Is Making a Play to Host the Oscars Leobait: Resisting AI Solutionism through Workplace Collective Action So ... is AI writing any good? Project Indigo We used AI to analyse three cities. It's true: we now walk more quickly and socialise less Hosts: Leo Laporte, Jeff Jarvis, and Paris Martineau Guest: Rich Skrenta Download or subscribe to Intelligent Machines at https://twit.tv/shows/intelligent-machines. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: pantheon.io helixsleep.com/twit

This Week in Google (Video HI)
IM 833: The Most Popular S3 Bucket Ever - AI Slop, Clankers, and Shrimp

This Week in Google (Video HI)

Play Episode Listen Later Aug 21, 2025 188:08 Transcription Available


AI data wars push Reddit to block the Wayback Machine China Launches Three-Day Robot Olympics Featuring Football and Table Tennis US government agency drops Grok after MechaHitler backlash, report says Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines The AI Was Fed Sloppy Code. It Turned Into Something Evil. | Quanta Magazine AI data centers made Americans' electricity bills 30% higher Sam Altman says 'yes,' AI is in a bubble Is the A.I. Sell-off the Start of Something Bigger? Thousands of Grok chats are now searchable on Google Opinion | Amy Klobuchar: I Knew A.I. Deepfakes Were a Problem. Then I Saw One of Myself. 2,178 Occult Books Now Digitized & Put Online, Thanks to the Ritman Library and Da Vinci Code Author Dan Brown Pluralistic: "Privacy preserving age verification" is bullshit (14 Aug 2025) How to use "skibidi" and other new slang added to Cambridge Dictionary YouTube Is Making a Play to Host the Oscars Leobait: Resisting AI Solutionism through Workplace Collective Action So ... is AI writing any good? Project Indigo We used AI to analyse three cities. It's true: we now walk more quickly and socialise less Hosts: Leo Laporte, Jeff Jarvis, and Paris Martineau Guest: Rich Skrenta Download or subscribe to Intelligent Machines at https://twit.tv/shows/intelligent-machines. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: pantheon.io helixsleep.com/twit

All TWiT.tv Shows (Video LO)
Intelligent Machines 833: The Most Popular S3 Bucket Ever

All TWiT.tv Shows (Video LO)

Play Episode Listen Later Aug 21, 2025 188:08 Transcription Available


AI data wars push Reddit to block the Wayback Machine China Launches Three-Day Robot Olympics Featuring Football and Table Tennis US government agency drops Grok after MechaHitler backlash, report says Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines The AI Was Fed Sloppy Code. It Turned Into Something Evil. | Quanta Magazine AI data centers made Americans' electricity bills 30% higher Sam Altman says 'yes,' AI is in a bubble Is the A.I. Sell-off the Start of Something Bigger? Thousands of Grok chats are now searchable on Google Opinion | Amy Klobuchar: I Knew A.I. Deepfakes Were a Problem. Then I Saw One of Myself. 2,178 Occult Books Now Digitized & Put Online, Thanks to the Ritman Library and Da Vinci Code Author Dan Brown Pluralistic: "Privacy preserving age verification" is bullshit (14 Aug 2025) How to use "skibidi" and other new slang added to Cambridge Dictionary YouTube Is Making a Play to Host the Oscars Leobait: Resisting AI Solutionism through Workplace Collective Action So ... is AI writing any good? Project Indigo We used AI to analyse three cities. It's true: we now walk more quickly and socialise less Hosts: Leo Laporte, Jeff Jarvis, and Paris Martineau Guest: Rich Skrenta Download or subscribe to Intelligent Machines at https://twit.tv/shows/intelligent-machines. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: pantheon.io helixsleep.com/twit

The Dr. Peter Breggin Hour
The Dr. Peter Breggin Hour - 8.20.25

The Dr. Peter Breggin Hour

Play Episode Listen Later Aug 20, 2025 58:00


Rarely is one of our shows as intricately fascinating and self-disclosing to our guest and ourselves that we cannot adequately describe all that we covered, all that we learned, and all that we began integrating anew into our knowledge as the interview evolved.   Our guest, physician Juliette Engel, was a captive, slave, and experimental subject controlled by the CIA from early childhood until age sixteen. Acting on her own, she then escaped the CIA/MKUltra house of devil worship — a subject we will let her tell you about in the interview. She began her new life as a college student, and to manage her severe post-traumatic stress, she developed amnesia for her horrendous past. As a therapist and researcher, I know this happens, but it requires a powerful mind like Dr. Engel to accomplish it and ultimately to flourish.   Dr. Engel is part of a growing number of people coming forth about their experiences as victims of CIA experiments, which in part were training her to become a part of what I have decided to call, “the global community of abusers without conscience,” a powerful aspect of the global predators and their unholy empires.   Adding incredible background to her personal testimony, she sent us in advance a document released from the National Security Archive on December 23, 2024. The ominous title is “CIA Behavioral Control Experiments Focus of New Scholarly Collection.”   The CIA documents confirm many of Dr. Engel's memories, which only began to unfold much later, after a life of medical reform work in Russia.   Confirming Our Own Experiences with the Deep State and CIA   One huge confirmation for me and Ginger is how much the CIA was indeed focused on defending and supporting the very kind or torturous and inhuman psychiatric treatments that I began openly opposing in the early 1970s, including lobotomy and other forms of psychosurgery and electroshock (ECT) which I have described as an electrical closed-head lobotomy.   Another insight for me was the similarity between the CIA agents and collaborators, as described in the CIA documents, and the global predators we have described in our book, COVID-19 and the Global Predators: We Are the Prey. This is the same profile we continue to explore in our recent columns about America's four current empires: the Western Global Empire, the Eastern Global Chinese Communist Empire, the Russian Empire, and the Caliphate Muslim Empire.   These predators, across a broad spectrum of activities, are primarily motivated by a lust for power over other human beings. They also desire wealth, but mostly as a tool for gaining power. What drives them is the desire to exert power over as many people as possible within their sphere, whether it is a political party, a criminal cabal or conspiracy, a government agency, a nation, an empire, or a global governance.   If they did not lust for power, they would not succeed in their goal of dominating, controlling, exploiting, enslaving, or killing as many people as possible. They must also possess extreme cunning and shrewdness to be able to manipulate and exploit so many people and to compete for power among so many other violent, cunning people. Probably above all else, they must be masters of conspiracy, able to seduce or intimidate others into helping them pursue their evil aims.   These predators must lack identification with the people within their own family,  group, nation, or empire, because seizing and growing enormous power usually requires, as history demonstrates, killing competitors in their own families and their own inner circles of co-conspirators, as well as millions of their own people, as demonstrated by apex global predators from Alexander “the Great” to Hitler, Stalin, Mao, and the current leaders of Communist China.   These predators must not allow themselves to genuinely love anyone, because such entanglements and feelings would check or inhibit the kind of evil conduct required for fulfilling their primary lust for power. Ultimately, they must not identify with anyone but themselves.   The following excerpts are taken from the vastly important document that our guest, Juliette Engel, MD, first drew to our attention, “CIA Behavior Control Experiments Focus of New Scholarly Collection.”  [The document lacks page numbers, but the excerpts can be located by means of searching the document:]   Excerpt 1 from the CIA Documents   Asked whether the CIA had tried to identify “techniques of producing retrograde amnesia,” Gottlieb said it was something that they “talked about,” but that he could not “remember any specific projects or specific research mounted in response to that question.” Asked if the CIA ever used “psychosurgery research projects,” Gottlieb said his “remembrance is that they did.”   Excerpt 2   The elevation of Allen Dulles to deputy director of central intelligence in 1951 led to an expansion of BLUEBIRD programs under a new name, ARTICHOKE, and under the direction of Gottlieb at TSS. The new program was to include, among other projects, the development of “gas guns” and “poisons,” and experiments to test whether “monotonous sounds,” “concussion,” “electroshock,” and “induced sleep” could be used as a means to gain “hypnotic control of an individual.”[5]   Excerpt 3   Another prominent MKULTRA “cutout” foundation, the Human Ecology Society, was run by Cornell Medical Center neurologist Dr. Harold Wolff, who wrote an early study of communist brainwashing techniques for Allen Dulles and later partnered with the CIA to develop a combination of drugs and sensory deprivation that could be used to erase the human mind. Among the most extreme MKULTRA projects funded through Wolff's group were the infamous “depatterning” experiments conducted by Dr. D. Ewen Cameron at the Allan Memorial Institute, a psychiatric hospital at McGill University in Montreal, Canada. Cameron's methods combined induced sleep, electroshocks, and “psychic driving,” under which drugged subjects were psychologically tortured for weeks or months in an effort to reprogram their minds.   Except 4   While no new techniques had been discovered, presently known mind control techniques described in the attachment include the use of LSD and other drugs, hypnosis, the use of the polygraph, neurosurgery, and electric shock treatments. However, field testing of these techniques has been handicapped by the “inability to provide the medical competence for a final evaluation and for such field testing as the evaluation indicates. Repeated efforts to recruit medical personnel have failed and until recently the CIA Medical Staff has not been in a position to assist.”   Excerpt 5   The response from TSS lists 17 “materials and methods” that the Chemical Division was working to develop, including:   *substances that “promote illogical thinking,” materials that would “render the induction of hypnosis easier” or “enhance its usefulness,” substances that would help individuals to endure “privation, torture and coercion during interrogation” and attempts at ‘brainwashing,'” *“materials and physical methods” to “produce amnesia” and “shock and confusion over extended periods of time,” substances that would “produce physical disablement, including paralysis, *substances that “alter personality structure” or that “produce ‘pure' euphoria with no subsequent let-down,” and a “knockout pill” for use in surreptitious druggings and to produce amnesia, among other things. [Asterisks and bold added]   Excerpt 6   Gibbons was not fully clear on how the CIA obtained LSD, but most of it came from the Eli Lilly & Company, according to this memo, which “apparently makes a gift of it to CIA.”  [bold added. There are many mentions in the report citing Eli Lilly as the source of massive of amounts of LSD which the CIA then inflicted upon Americans, sometimes as experiments and sometimes for financial gain.]   End of Excerpts   In the current release of CIA documents, many well-known government officials and universities are named as supporting and collaborating with MKUltra and other ghastly CIA experiments. Particularly stunning to me, the CIA bought a new wing for the Georgetown University Hospital, in return for which the CIA was given a special “safe house” inside the medical wing where they were free to inflict their wanton will on involuntary experimental subjects with supportive help from the hospital.   One More Step in Facing the Evil Within   These quotes confirm what I had long suspected and had only limited data to confirm — that the CIA and other government agencies are very protective and supportive of psychosurgery (lobotomy) and electroshock treatment (ECT). They want to research and apply these gross methods of damaging the human brain and mind to facilitate interrogation, to erase memories, to change personalities, and to make people more obedient and robotic. They also want them widely used in society to dumb down and render passive as many people as possible on the way to building the global slave state.   During this interview, we began to more deeply appreciate the involvement of the Deep State in psychiatry and psychology and the strength of their opposition to my reform work going back to the early 1970s. My earliest reform efforts focused on these two treatments, psychosurgery and then electroshock, and finally matured into seeing all psychiatric treatment as an assault on the brain and mind.   In various books and scientific articles, Ginger and I have been pointing to federal agencies pushing lobotomy (DOJ, NIMH), pushing electroshock (CIA, FDA), and pushing psychoactive drugs (FDA, CIA, NIMH, NIH, Department of Education, and others.   Our greatest confrontation with federal agencies came during an intense few years when we educated and organized people to shut down a massive U.S. interagency eugenical program to go into the inner cities to identify supposed biological and genetic causes of violence in black children and youth. The goal was ultimately to justify the widespread diagnosing and drugging of these children, including highly remunerative drugs like antidepressants and stimulants. I had already encountered outright racism, with neurosurgeons and psychiatrists advocating in print for the use of psychosurgery to control the leaders of black uprisings in the 1960s and early 1970s.   We completely defeated the massive eugenics project, causing the cancellation of a major conference and many research projects. We authored a book about it, The War Against Children of Color (1994), which addresses numerous Deep State actors such as the CDC, Department of Justice, FBI, NIMH, NIH, DHHS, and PHS, and names many perpetrators. But we had not yet seen the globalist scope of these activities. Here are links to a few articles about our successful efforts to stop the federal eugenics program.   The Role of Psychiatry in Nazi Germany and the U.S. Violence Initiative. This link contains the written introduction and historical video of Dr. Peter Breggin's presentation to Black leaders and community members in Harlem in the early 1990s about the federal government's plans to biologically “prevent violence” by identifying and drugging Black toddlers and children—a plan ultimately stopped due to the Breggins' exposure of the eugenics program. A biomedical programme for urban violence control in the US: the dangers of psychiatric social control; by Peter R Breggin and Ginger Ross Breggin Letter to the Editor, The New York Times by Peter R. Breggin, M.D.: U.S. Hasn't Given Up Linking Genes to Crime.  Excerpt: “Dr. Goodwin estimates that 100,000 children, as young as 5, will be identified for psychiatric interventions. He called the violence initiative the No. 1 funding priority for the Federal mental health establishment in 1994. My organization has since obtained documentation that millions of dollars of Federal funds are being spent on violence initiative research and planning, including studies of both rhesus monkeys and inner-city children. Newly developed psychiatric drugs are being tested for violence prevention in monkey studies, and some psychiatrists are claiming they can be used in humans for the same purpose. It seems inevitable that the violence initiative will involve administering the same drugs to inner-city children. The widespread use of Ritalin to control aggressive children, frequently supported or initiated by public schools, has set a precedent for pharmacological intervention.” Disposable Children in Black Faces: The Violence Initiative as Inner-City Containment Policy; Alfreda A. Sellers-Diamond, UMKC Law Review, 1994. Campaigns Against Racist Federal Programs by the Center for the Study of Psychiatry and Psychology; Peter R. Breggin, Journal of African American Men, 1995. NIH, under fire, freezes grant for conference on genetics and crime; Nature, Vol. 358, 30 July 1992, p357.   It was further hammered home to me in the interview with Dr. Engel that the kinds of individuals who are cunning enough and violent enough to run totalitarian nations and empires have their counterparts running amok within many federal agencies and many other American institutions. And that is the force from within that we are fighting today as we stand up for freedom in America. We must face a former national leadership, and a current Deep State and other institutions riddled with the worst human beings we can imagine and understand — or we will remain vastly hampered in fighting them.     ______   Learn more about Dr. Peter Breggin's work: https://breggin.com/   See more from Dr. Breggin's long history of being a reformer in psychiatry: https://breggin.com/Psychiatry-as-an-Instrument-of-Social-and-Political-Control   Psychiatric Drug Withdrawal, the how-to manual @ https://breggin.com/a-guide-for-prescribers-therapists-patients-and-their-families/   Get a copy of Dr. Breggin's latest book: WHO ARE THE “THEY” - THESE GLOBAL PREDATORS? WHAT ARE THEIR MOTIVES AND THEIR PLANS FOR US? HOW CAN WE DEFEND AGAINST THEM? Covid-19 and the Global Predators: We are the Prey Get a copy: https://www.wearetheprey.com/   “No other book so comprehensively covers the details of COVID-19 criminal conduct as well as its origins in a network of global predators seeking wealth and power at the expense of human freedom and prosperity, under cover of false public health policies.”   ~ Robert F Kennedy, Jr Author of #1 bestseller The Real Anthony Fauci and Founder, Chairman and Chief Legal Counsel for Children's Health Defense.

Idaho Matters
Idaho Matters Doctor Roundtable: August 20, 2025

Idaho Matters

Play Episode Listen Later Aug 20, 2025 33:46


Hundreds of people may have been exposed to rabies in Wyoming, Eli Lilly has a new GLP-1 pill to help people lose weight and doctors may become dependent on AI.

Diabetes Connections with Stacey Simms Type 1 Diabetes
In the News... GLP-1 oral pill moves forward, Medtronic-Abbott sensor unveiled, Afrezza submitted for kids, diabetes scholarships and more!

Diabetes Connections with Stacey Simms Type 1 Diabetes

Play Episode Listen Later Aug 15, 2025 10:02


 It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: cancer reserach may lead to T1D treatment, GLP-1 oral pill moves forward, Tandem pharmacy moves, Medtronic-Abbott sensor unveield, parents of kids with T1D see income drop, Mannkind submits Afrezza for pediatrics, diabetes scholarships and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Cornell researchers have developed an implant system that can treat type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression. The system could also potentially provide long-term treatment for a range of chronic diseases. This lab has produced previous implantable devices that have proved effective in controlling blood sugar in diabetic mice, but they can only last so long. "It's the proof of concept. We really proved that oxygenation is important, and oxygenation will support high cell-density capsules," Tempelman said. "The capsules are immune protective and last for a long time without having some kind of fouling of the membrane. The body never likes it when you put a foreign substance in. So that's the engineering in the Ma Lab, to look for materials and coatings for the materials that are immune protective, but also don't invoke excess response from the body because of the material." The next step will be to implant the system in a pig model, and also test it with human stem cells. The researchers are interested in eventually trying to use the system for implanting different cell types in humans for long-term treatment of chronic diseases, according to Tempelman, who is CEO of Persista Bio Inc., a new startup she founded with Ma and Flanders that is licensing these technologies. https://medicalxpress.com/news/2025-08-implant-diabetes-oxygenating-insulin-cells.html XX Mayo Clinic cancer research may be big news for T1D. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1. Cancer cells use a variety of methods to evade immune response, including coating themselves in a sugar molecule known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it's possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells. The findings show that it's possible to engineer beta cells that do not prompt an immune response   In the preclinical models, the team found that the engineered cells were 90% effective in preventing the development of type 1 diabetes. The beta cells that are typically destroyed by the immune system in type 1 diabetes were preserved.     https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-find-sugar-coating-cells-can-protect-those-typically-destroyed-in-type-1-diabetes/ XX A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.   The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive.   Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. https://www.nytimes.com/2025/04/17/health/pill-glp-1-eli-lilly.html XX Use of diabetes technology has dramatically increased and glycemic control has improved among people with type 1 diabetes (T1D) in the US over the past 15 years, but at the same time, overall achievement of an A1c level < 7% remains low and socioeconomic and racial disparities have widened. These findings came from an analysis of national electronic health records of nearly 200,000 children and adults with T1D by Michael Fang, PhD, of the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues. The study was published online on August 11, 2025, in JAMA Network Open. Use of continuous glucose monitors (CGMs) increased substantially from 2009-2011 to 2021-2023, from less than 5% in both children and adults to more than 80% and over half, respectively. While A1c levels did drop over the 15 years, just 1 in 5 children and slightly over a quarter of adults achieved a level < 7%. The average A1c level stayed above 8%, with ethnic minorities and low-income patients seeing the smallest gains.       https://www.medscape.com/viewarticle/diabetes-tech-use-rise-a1c-reductions-still-lag-2025a1000lc9 XX Inflammation may predict how well people with diabetes respond to depression treatment, and the effects differ dramatically between type 1 and type 2 diabetes. Diabetes and depression often appear together. Indeed, depression is more than three times more prevalent in people with type 1 diabetes (T1D) and nearly twice as prevalent in people with type 2 diabetes (T2D). When they appear together, treatment for depression can vary widely. In a new study, researchers from the German Diabetes Center (DDZ), the Research Institute of the Diabetes Academy Mergentheim (FIDAM), and the German Center for Diabetes Research (DZD) investigated how inflammation in the body relates to improvement in depression symptoms in people with T1D and T2D. The researchers combined data from three previous German randomized clinical trials that aimed to reduce elevated depressive symptoms and diabetes distress in people with type 1 or type 2 diabetes. Diabetes distress is characterized by feelings of overwhelm, frustration, guilt and worry about diabetes management and its potential complications. A total of 332 participants with T1D and 189 with T2D who had completed both a baseline and 12-month follow-up examination were included in the present study. Measures included depression using the Center for Epidemiological Studies Depression scale (CES-D), blood tests for 76 inflammatory biomarkers, and symptoms broken down into cognitive-affective (e.g., feeling hopeless), somatic (e.g., poor sleep, fatigue), and anhedonia (loss of pleasure) clusters.   After adjusting for factors like age, body mass index (BMI), diabetes duration, cholesterol, and co-existing illnesses, the researchers found that in patients with T1D, higher baseline inflammation was linked to smaller improvements in depression. Inflammation seemed to be more connected to physical/somatic symptoms in T1D patients. In those with T2D, higher baseline inflammation was linked to greater improvements in depression. For these patients, the effect was strongest for cognitive-affective and anhedonia – so, emotional and motivational – symptoms.   The researchers weren't sure what caused the difference between T1D and T2D, but they suggest it might be due to the different forms of immune activation seen in each condition. That is, autoimmune processes in type 1 and metabolic inflammation in type 2. https://newatlas.com/health-wellbeing/inflammation-diabetes-depression-treatment/ XX Parents of children diagnosed with type 1 diabetes suffer an income drop in the years following the diagnosis. The impact is more pronounced in mothers, especially mothers of children diagnosed in preschool years. And these findings come from a European study.. not the US. Previous research has shown that parents of children with type 1 diabetes are at increased risk of stress-related symptoms and may need to reduce their working hours. "In our study, we observed reduced parental work-related incomes in the years following the child's type 1 diabetes diagnosis. The drop was larger in mothers than in fathers. Since mothers earned significantly less than fathers in absolute terms, even before the child fell ill, the relative drop in mothers was 6.6% the year following diagnosis compared to 1.5% in fathers. We further note the greatest impact on work-related incomes in mothers of children diagnosed at preschool age," says Beatrice Kennedy, physician at the Endocrine and Diabetes unit at Uppsala University Hospital and Associate Professor of Medical Epidemiology at Uppsala University, who led the study. This is a huge study, builds on data from national population and health registers and the Swedish Child Diabetes Register (Swediabkids). The study includes the parents of more than 13,000 children diagnosed with type 1 diabetes in Sweden in 1993−2014, as well as more than half a million parents in the general population who have children not diagnosed with diabetes.   The researchers observed that the maternal pension-qualifying incomes (a composite outcome including work-related income and societal benefits) initially increased after the child's diagnosis. This was attributable to mothers applying for the parental care allowance from the Swedish Social Insurance Agency. The parental care allowance was intended to compensate for disease-related loss of work-related income and contribute toward disease-specific costs.   When the research team investigated long-term effects in mothers, they found that the pension-qualifying incomes gradually decreased after eight years, and had not recovered by the end of follow-up − 17 years after the children were diagnosed. https://www.news-medical.net/news/20250811/Mothers-face-greater-financial-impact-following-childe28099s-type-1-diabetes-diagnosis.aspx XX The U.S. Department of Justice has reached a settlement with Metro Nashville Public Schools after allegations that the district violated the Americans with Disabilities Act.   The parents of a student at the Ross Early Learning Center requested that the school monitor their child's glucose monitor. Investigators found the school refused to do so, despite the child's Type 1 Diabetes diagnosis.   As part of the settlement, MNPS agreed to change its policies to allow the use of these devices, ensure trained staff can monitor them throughout the entire school day and at school activities, and improve communication with parents. https://www.wsmv.com/2025/08/12/metro-nashville-public-schools-settles-allegations-it-discriminated-against-students-with-diabetes/ XX Modular Medical has unveiled Pivot, its next-generation insulin patch pump technology aimed at simplifying diabetes care. The company announced its new pump for “almost-pumpers” at the Association of Diabetes Care & Education Specialists (“ADCES”) Conference in Phoenix, Arizona this weekend. It aims for Pivot to target adults with a user-friendly, affordable design.   Modular Medical's current pump, the MODD1, won FDA clearance nearly a year ago. It features new microfluidics technology to allow for the low-cost pumping of insulin. The system has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery.   The company announced recently that it validated its insulin pump cartridge line for human-use production in the U.S. Days later, it reported the first human use of the MODD1 pump.   Now, it has taken the next steps with the debut of a next-gen pump, set for FDA submission in October.   Modular Medical also gamifies diabetes care The company also said ADCES is the place where it will showcase the first playable level of its new Pivot pump gamified trainin module. Level Ex, a developer of medical games, develops the module.   Modular Medical said gamification offers a way to make medical training more effective and efficient while improving information retention. Given the complexity in pump uptake, the company hopes to provide an easy way to bring its technology to clinicians and patients.   The company expects to have training modules available at the same time as the pump's planned launch in 2026.   “Level One is free because diabetes mastery shouldn't come with a price tag,” Sam Glassenberg, CEO of Level Ex, said. “Modular Medical is breaking barriers too – bringing pump therapy to more people through smart, accessible design. Together, we intend to make diabetes management simpler and more inclusive.   “People learn best through play – and we believe they want to learn about insulin pumps the same way. In Level One, players aren't just mastering diabetes management through gameplay – they're asking to ‘play' with pumps: to explore how they work, understand their benefits, and build confidence before using them in real life. Our partnership with Modular Medical helps make that possible.” https://www.drugdeliverybusiness.com/modular-medical-unveils-next-gen-insulin-pump/ XX On Tuesday, 12 August 2025, Tandem Diabetes Care (NASDAQ:TNDM) presented at the Canaccord Genuity's 45th Annual Growth Conference, outlining strategic shifts and market focus. The company highlighted its plans for commercial transformation in the U.S. and expansion in international markets, alongside addressing competitive challenges and regulatory impacts. While optimistic about growth in Outside the U.S. (OUS) markets, Tandem is navigating a more competitive landscape domestically. We have entered into the pharmacy channel with Mobi only. And so as Mobi's been building up volume, we're getting experience and we're really learning and understanding what pharmacy offers to us. And the proof points have proved out the thesis I said earlier, which is it can really reduce that barrier for patients, is the out of pocket cost. And so we've decided to accelerate our strategy and where we were starting just with Mobi, we are now moving t slim supplies into the pharmacy channel, and that will kick into gear in the fourth quarter. So as people are looking at the cadence of sales for the remainder of the year with this reframing, many folks are seeing what looks like a a might be an outsized fourth quarter and and having trouble understanding those dynamics. We'll be adding the tSIM supplies to those contracts. We also have more coverage. We will have it in the coming weeks effective this year, so we will be increasing that 30% rate before the end of the year. And then, obviously, everyone's in the same cycle right now already negotiating and discussing their 2026 coverage. And so 30% is the floor.   We do expect to continue to grow that coverage in the coming years, and ultimately have a much broader access. Absolutely. It's an exciting technology that allows for us to have an infusion set that extends the wear time from three days to up to seven days. So we're able to use that as part of an independent infusion set, which would then be used with the t slim and with the mobi pump today. But we're also using that same technology as part of the site that's used for mobi when you use it with a tubeless cartridge. So next year, we will launch Mobi in a patch configuration.   It uses the same pump that's available today, but by using a modified cartridge, you're able to wear it as a patch pump. So one of the things we announced on the call is that we're using this extended wear technology as part of that site. So what it allows you to do is to change the portion that you wear in your skin separate from the timing of when you change the insulin cartridge. So it allows for that extended wear time, reduction of burden to the patient, which is especially important for higher volume insulin users as we expand into type two. So from here, we will launch the extended wear site next year along with we'll do a separate regulatory filing for the cartridge portion for Mobi that includes this extended wear technology as a predicate device. So that's another filing that we'll need to do, but we have the clearance today for the independent infusion set, but we'll file another five ten k for use of the extended wear technology as part of the tubeless Mobi feature. https://za.investing.com/news/transcripts/tandem-diabetes-at-canaccord-conference-strategic-shifts-and-market-focus-93CH-3834464 XX MannKind today announced a significant regulatory submission and a large financing agreement with Blackstone. The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said.   First, the Danbury, Connecticut-based company announced that it submitted a supplemental Biologics License Application (sBLA) for Afrezza, its inhaled insulin product, in the pediatric population.   MannKind Director of Medical and Scientific Engagement Joanne Rinker, MS, RDN, BC-ADM, CDCES, LDN, FADCES, told Drug Delivery Business News at ADA 2025 that a submission was on the way for children and adolescents aged 4-17 years old. Further data shared at ADA found Afrezza both safe and effective in that age range.   Afrezza is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to slowly bring powder into the lung. A small compartment opens for the insertion of the insulin cartridge, then the user closes it. The only other component is a mouthpiece for the sake of cleanliness. Then, the inhalation takes just two seconds. It requires no electronics or extra components.   The company expects a review acceptance decision early in the fourth quarter of 2025.   “The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes,” said Michael Castagna, CEO of MannKind Corporation.   Additional funding provides a significant boost for MannKind MannKind also announced a strategic financing agreement with funds managed by Blackstone worth up to $500 million. The financing provides MannKind with non-dilutive capital to advance its short- and long-term growth strategies.   This senior secured credit facility includes a $75 million initial term loan funded at closing. It then has a $125 million delayed draw term loan available for the next 24 months. Finally, it features an additional $300 million uncommitted delayed draw term loan available at the mutual consent of MannKind and Blackstone.   The facility bears interest at a calculated SOFR variable rate plus 4.75% and matures in August 2030.   “This strategic financing significantly increases our operating flexibility and provides us substantial access to non-dilutive capital on favorable terms, complementing our strong cash position,” said Castagna. “The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes. Partnering with the Blackstone team on this transaction positions us to accelerate our next phase of growth and innovation.” https://www.drugdeliverybusiness.com/mannkind-fda-submission-pediatrics-500m-blackstone/ XX   Medtronic MiniMed Abbott Instinct Sensor [Image from Medtronic Diabetes on LinkedIn] The Medtronic Diabetes business today took to social media to share an early preview of a new integrated Abbott sensor for its insulin delivery systems. Medtronic Diabetes — soon to be MiniMed after its planned separation from the medtech giant – said in the post that the new sensor specifically designed for its own systems is called “Instinct.”   “Get a sneak peek at what's coming next: the Instinct sensor,” the business unit's account wrote. “Made by Abbott, the Instinct sensor is designed exclusively for MiniMed systems. We'll share more details about the Instinct sensor when it's commercially available.”   The sensor, built on the Abbott FreeStyle Libre platform, reflects “the power of the partnership,” Abbott EVP, Diabetes Care, Chris Scoggins, told Drug Delivery Business News earlier this year.   Medtronic and Abbott — two of the largest diabetes tech companies in the world — announced a year ago that they entered into a global partnership pairing Abbott continuous glucose monitors (CGMs) with Medtronic insulin delivery systems.   The partnership aims to collaborate on a system based on Abbott's FreeStyle Libre CGMs with Medtronic's automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as the InPen system.   Read more about Medtronic, Abbott and the rest of the diabetes tech industry in our free Diabetes Technology Special Report. Medtronic's systems previously used its own CGMs, such as the Guardian 4 and the Simplera platform, and the company intends to continue using those systems as part of a comprehensive CGM portfolio. Under the companies' agreement, the systems would be sold exclusively by Medtronic — including the Abbott CGM.   The companies brought the partnership a step further in April when Medtronic announced the submission of an interoperable pump with the Abbott sensor technology to the FDA. They plan to share more details following the expected FDA clearance, which remains pending.   Management also recently emphasized the multi-year nature of the partnership, meaning Medtronic could pair current and future pumps with other Abbott sensors in the future. That could hint at integration with the company's future dual glucose-ketone monitor, as a number of pump makers have already announced collaborations to pair their systems with the sensor once it hits the market. https://www.drugdeliverybusiness.com/medtronic-diabetes-previews-abbott-sensor-minimed/ XX Governor Glenn Youngkin joined Civica officials at the company's Petersburg manufacturing facility to announce a $3 million grant from the Commonwealth of Virginia to accelerate Civica's efforts to develop and produce affordable insulin for Americans living with diabetes.   CivicaRx Logo   "We are proud to partner with Civica in their mission to make essential medicines more accessible," said Governor Youngkin. "This investment reflects our belief in the power of public-private collaboration to improve lives and strengthen communities."   These funds will support the production of insulin aspart, a rapid-acting human insulin analog used to regulate blood sugar in adults and children with diabetes. Civica plans to produce both rapid- and long-acting insulins at its state-of-the-art manufacturing facility in Petersburg, Va., where the company now employs more than 200 skilled workers.1 Over 8 million people living with diabetes need rapid-acting and/or long-acting insulin.   The Governor also announced that he had officially proclaimed August 7 – 14 2025 'Life Sciences Week' demonstrating the Commonwealth's commitment to "accelerating the advancement of the life sciences through public-private partnerships, STEM education, workforce development, and sustained investment in research and development."   "We are grateful for the Commonwealth's support," said Ned McCoy, Civica's President and CEO. "This funding will help us move closer toward our goal of ensuring that no one has to choose between insulin and other basic needs."   Civica and Virginia officials were joined by Lynn Starr, Chief Global Advocacy Officer of Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization.   "More than one million American adults live with type 1 diabetes, and many still, sadly, ration their insulin, due to the prohibitively high cost of this necessary medication," said Starr.  "Civica's work will help to make insulin more affordable for people across the country."   Breakthrough T1D is among more than two dozen organizations and philanthropists, along with the states of Virginia and California, that have partnered with Civica to support the development of affordable insulins.   Civica's insulin initiative aims to provide patients with predictable, transparent pricing — no more than $30 per vial or $55 for a box of five pens — regardless of insurance status.   About Civica Civica is a nonprofit pharmaceutical company established to address drug shortages. It was founded by a group of U.S. health systems and philanthropies who, after more than a decade of chronic shortages, recognized that the market was not self-correcting and that a different approach is required. Civica works to deliver a safe, stable, and affordable supply of essential medicines to U.S. patients.   Media Contact: Liz Power liz.power@civicarx.org +1 860 501 3849 https://cbs4indy.com/business/press-releases/cision/20250807NY46213/governor-glenn-youngkin-announces-3-million-grant-to-support-civicas-affordable-insulin-programs/ XX If you or someone you love is living with diabetes, you already know the fight isn't just medical—it's financial, too. Between daily supplies, doctor visits, and long-term care, the cost of managing type 1 or type 2 diabetes can be overwhelming. Add college or trade school into the equation, and suddenly staying healthy competes with building a future. That's where scholarships for students with diabetes—like Beyond Scholars and others listed here—step in.   Whether you're headed to a university, a two-year college, or a hands-on trade program, these opportunities were created to ease the load.   Scholarships for students with diabetes Beyond Scholars (from Beyond Type 1): $10,000 for recently graduated high school seniors with type 1 diabetes or type 2 diabetes entering college or trade school. This is one of the largest needs-based diabetes scholarships in the United States. This year, awardees will also receive 6 months of wellness coaching through Risely Health.   Applications open: July 25, 2025 Deadline: August 29, 2025 Winners announced: October 2025 https://beyondtype1.org/beyond-scholars-diabetes-scholarships-college-trade-school/ XX Nick Jonas and Kyle Rudolph are using their platforms for a good cause.   On Tuesday, Aug. 12, the singer and the former NFL tight end (via his professional fundraising platform Alltroo) announced they're teaming up to launch a rally featuring a fan-coveted prize: a custom 2025 Volkswagen ID. Buzz electric bus that the Jonas Brothers have brought along for their 20th anniversary tour.   “Ten years ago, we hit the road with a goal to change what it means to live with diabetes. Since then, Beyond Type 1 has grown into the world's largest digital diabetes community, offering the tools, education, and peer support needed to not only survive but thrive with diabetes,” Jonas, who co-founded Beyond Type 1 (a nonprofit that advocates for those living with diabetes), says in a statement.     “We've challenged stigma, built community, provided life-saving resources, and collectively driven global innovation toward prevention and cure. This milestone is a moment to rally even more support for our mission, and partnering with Alltroo helps us do that in a powerful, engaging way.”   Related Stories Nick Jonas on Managing His Diabetes: 'The Mental and Emotional Health Aspect Is Really Important' nick jonas Nick Jonas Says He Was Diagnosed with Diabetes After Joe Told Their Parents: 'Something's Really Wrong' Joe Jonas and Nick Jonas attend the amfAR Cannes Gala 30th edition at Hotel du Cap-Eden-Roc on May 23, 2024 For Rudolph, the campaign is about "celebrating Beyond Type 1's incredible work over the past decade, and standing behind their vision of a world where everyone with diabetes — or at risk of it — has access to the knowledge, care and support needed for early diagnosis and lifelong health."   While the rally is live on Alltroo.com, fans can also scan QR codes available at all 36 Jonas Brothers concert stops to enter for a chance to win the electric bus. (A winner will be selected on November 14, which is World Diabetes Day.)   Jonas, 32, has long been open about his Type 1 diabetes diagnosis at 13 years old. "I had this kind of wrench thrown into things when I was diagnosed and it took a while to figure out how to count carbs to properly dose for insulin and what things would affect me in different ways," he previously told PEOPLE.   "When I was first diagnosed, I was sitting in the hospital and was scared to death, honestly, while I was learning about how to manage this new thing I was dealing with," Jonas recalled. "It would have been amazing to have someone to look at at that time to say, oh, this is a person living with it and they're following their dreams. They're doing what they want to do with their lives and not letting it slow them down."           https://people.com/nick-jonas-kyle-rudolph-launch-fan-rally-diabetes-awareness-11788684

Squawk on the Street
Cramer's Morning Take: Eli Lilly 8/13/25

Squawk on the Street

Play Episode Listen Later Aug 13, 2025 3:22


Cramer says he wants to buy back shares of this pharma giant. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market's biggest headlines. Signup here: cnbc.com/morningtake CNBC Investing Club Disclaimer

Morning Announcements
Friday, August 7th, 2025 - TX gerrymander update; OH river raised for VP; 401Ks go crypto; Eli Lilly's new weight loss pill & more

Morning Announcements

Play Episode Listen Later Aug 8, 2025 7:44


Today's Headlines: We're ending the week on a truly chaotic note. Texas Senator John Cornyn got the FBI involved to help track down state Democrats who fled to avoid a rushed redistricting vote—one that would give Republicans five extra seats, just because Trump said they should have them. Trump's also pushing for early redistricting in other red states and floated a new census that would exclude undocumented immigrants—never mind what the Constitution says. In other news, he signed an order demanding colleges hand over race-based admissions data, and the Air Force is cutting off early retirement benefits for transgender service members. Additionally, Trump now wants your 401(k) to dabble in crypto and real estate, and he's nominating an aide to the Fed who's big on lowering interest rates. Finally, Apple CEO Tim Cook gave Trump a weird gold iPhone trophy, VP JD Vance's river was allegedly raised for his birthday kayak trip, Israel confirmed it plans to take full control of Gaza, and Eli Lilly released promising results from a study of its new weight loss pill. Resources/Articles mentioned in this episode: NBC News: Sen. John Cornyn says the FBI granted his request to help find absent Texas Democrats WaPo: Led by Trump, Republicans push to redraw election maps in multiple states Axios: Trump says he's ordering a new census. Here's what the Constitution says Axios: Trump orders colleges to report race data AP News: Trump's Air Force denies retirement pay to ex-trans service members Axios: Trump to supercharge private equity with 401(k) order PBS: Trump says he is nominating top economic aide Stephen Miran to Federal Reserve board The Verge: Apple made a 24k gold and glass statue for Donald Trump AP News: JD Vance went kayaking for his birthday. Secret Service had the river level raised AP News: Netanyahu says Israel plans to take over Gaza to destroy Hamas Wired: Eli Lilly's Obesity Pill Shows Promising Weight Loss in New Results Morning Announcements is produced by Sami Sage and edited by Grace Hernandez-Johnson Learn more about your ad choices. Visit megaphone.fm/adchoices

Kendall And Casey Podcast
New weight loss pill from Eli Lilly

Kendall And Casey Podcast

Play Episode Listen Later Aug 8, 2025 5:06 Transcription Available


See omnystudio.com/listener for privacy information.